Arcutis Biotherapeutics Inc (ARQT) Stock Price, Quote & News

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 418 5006

Website: www.arcutis.com

Address:

3027 Townsgate Road, Suite 300, Westlake Village, United States

Hottehueh May. 12 at 5:13 PM

$ARQT good buying opportunity..

0 · Reply

Rhody27 May. 11 at 6:09 PM

$ARQT still in the penalty box.

0 · Reply

BioTechHealthX May. 10 at 5:17 PM

$ARQT Arcutis Biotherapeutics may have pulled back recently, but ZORYVE net product revenue surged 65% year-over-year in Q1 2026. With strong demand, pediatric expansion plans, and a growing dermatology footprint, ARQT could be one of biotech’s most interesting comeback names. https://biotechhealthx.com/biotech-news/should-you-now-start-investing-in-arcutis-biotherapeutics-arqt/

0 · Reply

BioTechHealthX May. 10 at 4:21 AM

$ARQT $CDNA $NBIX $VCYT $BHVN These top 5 biotech stocks to buy for May 2026 are not just random healthcare names. With projected EPS growth reaching up to 215%, rising sales expectations, precision medicine exposure, and high-risk, high-reward biotech potential, this list could grab serious investor attention. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-to-buy-with-up-to-215-projected-eps-growth/

0 · Reply

ZManicItalian May. 8 at 4:08 PM

$ARQT added. Gap closed from late Oct 🍻🐂

0 · Reply

DonCorleone77 May. 7 at 9:09 PM

$ARQT Attached is a MIzuho analyst note regarding ARQT issued today.

1 · Reply

5StarTrader May. 7 at 7:16 PM

$ARQT Last quarter they beat on both revenue and earnings and the same thing happened to the share price. The action is nothing but the machinations of the Market Maker Mafia with their futures contracts license to steal. Because both last quarter and this quarter showcased stellar results that indicate great performance and tremendous growth ahead. My take on it is “Be greedy when others are fearful.” ~ Warren Buffett, the Sage from Omaha.

0 · Reply